John Radcliffe Hospital, Level 4, Headley Way, Headington, Oxford, OX3 9DU
ORB Collections Governance Manager, Oxford Radcliffe Biobank
After completing my BSc in Biochemistry from Imperial College, which included a year working at the EMBL labs in Heidelberg, I returned to my native France for an MSc in Differentiation, Genetics and Immunology, at the Université Claude Bernard, in Lyon. I then returned to the UK to do a PhD in Cellular and Molecular Biology, at the University of Sheffield, working in the lab of Professor Claire Lewis. The project involved using prokaryotic transcription factors and response elements to develop an oxygen-sensitive suicide gene therapy system that might target the hypoxic and anoxic regions of tumours.
From Sheffield, I moved to the University of Oxford in 2001, joining the Gene Medicine Group, under the direction of Steve Hyde and Deborah Gill, and in collaboration with the UK Cystic Fibrosis Gene Therapy (CFGT) Consortium. During my 13 years in this group, I contributed to the development of a range of gene therapy vectors and their assessment by qPCR (titration of viral vectors, measurement of gene expression in cell culture and pre-clinical models, quantification of DNA delivery in pre-clinical and human samples), ultimately providing a number of molecular assays for a Phase II clinical trial of the first multidose non-viral gene therapy trial for CF aiming to demonstrate efficacy.
In 2014, as the CFGT Consortium research programme entered a new iteration of vector development ahead of future clinical trials, I moved to another team: The Oxford Radcliffe Biobank, then part of the same Nuffield Division of Clinical Laboratory Sciences I had been part of since my arrival in Oxford. Here I started off as Operations and Quality Manager, supporting the Biobank manager and the Data and Research Coordinator to keep the Biobank compliant with regulatory requirements, whilst providing advice on project requiring access to human samples, under ORB ethics. My role has now evolved to include broader governance of tissue collections under ORB as well as coordinating the ORB/OCHRe tissue access committee. This committee assesses research proposals and provides ethical approval for projects that fit under the ORB protocol and compliance oversight for projects with their own ethical approval. I manage a varied team, including a data manager, IT manager, clinical trial project coordinator and clinical trials administrator, a data and research coordinator (for non-clinical trial projects), and two histology technicians. By working together we support dozens of clinical trials requiring access to pathology services at the John Radcliffe Hospital and even more projects run by researchers across the University of Oxford and the OUH NHS Foundation Trust, investigating cancer as well as other conditions.
TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
Eyres M. et al, (2021), Gastroenterology, 161, 653 - 668.e16
The Potential of Artificial Intelligence to Detect Lymphovascular Invasion in Testicular Cancer.
Ghosh A. et al, (2021), Cancers (Basel), 13
Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments.
Kanellakis NI. et al, (2020), Thorax, 75, 1004 - 1008
The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial Cells.
Hu Z. et al, (2020), Cancer Cell, 37, 226 - 242.e7
Enriched HLA-E and CD94/NKG2A interaction limits antitumor CD8+ tumor-infiltrating T lymphocyte responses.
Abd Hamid M. et al, (2019), Cancer Immunol Res